<div id="readability-page-1"><p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) traded up 5.6% on Monday following a better than expected earnings announcement. The stock traded as high as $117.60 and last traded at $118.54. 231,459 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 683,737 shares. The stock had previously closed at $112.21.</p><div><p><span></span><span>Get <strong>Axsome Therapeutics</strong> alerts:</span></p></div><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.23) by $0.43. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. </p><h2>Analyst Upgrades and Downgrades</h2><p>AXSM has been the subject of a number of research reports. William Blair  restated an &#34;outperform&#34; rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. HC Wainwright  reaffirmed a &#34;buy&#34; rating and issued a $200.00 target price on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. Cantor Fitzgerald  restated an &#34;overweight&#34; rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, April 29th. Finally, Truist Financial lifted their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 19th. One investment analyst  has rated the stock with a hold rating and sixteen have assigned  a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $169.87.</p><ul><li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li></ul><p><b>View Our Latest Stock Report on Axsome Therapeutics</b></p><h2>Insiders Place Their Bets</h2><p>In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders own  22.40% of the company's stock. </p><h2>Institutional Trading of Axsome Therapeutics</h2><ul><li>Why this is an Awesome Time to Buy Axsome Therapeutics</li></ul><p>A number of institutional investors have recently bought and sold shares of the company. Edgestream Partners L.P. bought a new stake in shares of  Axsome Therapeutics during the 1st quarter valued at about $8,174,000.  New York State Common Retirement Fund lifted its position in shares of  Axsome Therapeutics by 49.3% during the 1st quarter. New York State Common Retirement Fund now owns 33,581 shares of the company's stock valued at $3,917,000 after acquiring an additional 11,090 shares during the period.  Mutual of America Capital Management LLC boosted its stake in  Axsome Therapeutics by 0.3% during the first quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company's stock worth $4,621,000 after acquiring an additional 136 shares in the last quarter.  Xponance Inc. increased its position in  Axsome Therapeutics by 8.7% in the 1st quarter. Xponance Inc. now owns 2,891 shares of the company's stock valued at $337,000 after buying an additional 232 shares in the last quarter.  Finally, Cerity Partners LLC increased its holdings in shares of  Axsome Therapeutics by 15.5% during the first quarter. Cerity Partners LLC now owns 5,707 shares of the company's stock valued at $666,000 after acquiring an additional 766 shares in the last quarter. Institutional investors own  81.49% of the company's stock. </p><h2>Axsome Therapeutics Stock Performance</h2><p>The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -19.64 and a beta of 0.46. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The company's fifty day simple moving average is $113.58 and its two-hundred day simple moving average is $104.02. </p><h2>About Axsome Therapeutics</h2> (Get Free Report)<p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Axsome Therapeutics</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>3 Stocks to Watch as Bitcoin Nears $100k Again</li><li>EV Stocks and How to Profit from Them </li><li>Amazon: Why The Great Comeback Rally Could Be About to Begin</li><li>3 Small Caps With Big Return Potential</li><li>3 Reasons Tesla Should Be a $300 Stock by June</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p><p>While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AXSM

<p>Axsome Therapeutics (NASDAQ:AXSM) shares rose 5.6% following a better-than-expected earnings report, with the stock last trading at $118.54. The company reported an EPS of ($0.80), surpassing estimates of ($1.23). Analysts have given the stock a "Moderate Buy" rating, with an average target price of $169.87. Institutional investors own 81.49% of the company, and recent trading activity shows a significant interest in the stock. Axsome focuses on developing therapies for CNS disorders, with products like Auvelity and Sunosi.</p>

Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.6% on Better-Than-Expected Earnings